After diagnosis, patients look at processing the diagnosis, connecting to the hospital, seeking knowledge (initial understanding of the disease) and gathering resources (e.g. social support).
Decision-making is most important for the patient's emotional well-being. Interactions with doctors, friends and support groups allow patients to:
u understand the outcomes of options, u consider the personal value by helping to clarify preferences, u feel supported in decision-making, u move through the steps in making a decision, presented by Dr. Andrew Mathew summary by John Arnold u participate in deciding about care.
After treatment, some patients must deal with urinary incontinence. In the long term, however, over 90% of men do not find it affects their quality of life. The key is to be patient, seek medical advice and do kegel exercises.
60% of patients report moderate to severe distress with sexual dysfunction.
Distress is especially elevated in younger men. Often partners experience greater stress.
Assistive aids for sexual dysfunction vary in invasiveness and effectiveness:
u Oral medications [PDE-S inhibitors] are effective in 30 to 60% in patients u Injections -85% effective, u Micro-suppositories -57% effective, u Vacuum device -80% effective, u Penile implants have satisfaction rates of 85%.
Findings suggest key psychological factors such as relationship conflict, anxiety, longing for spontaneity, and loss of sexual interest enter into the equation.
PCCN Ottawa Mission Statement
We provide information on prostate cancer to those in need, gathered from a variety of sources. We participate in events that provide a venue for promoting awareness of prostate cancer through our informed member interaction at public gatherings or as speakers. We expect a limited supply of padded chairs for the May meeting. We will continue to set up more tables to be available for group discussions. The Welcome committee requests that all attendees please sign the Meeting register on arrival.
Results of telephone canvass reviewed. Input is extremely helpful in identifying issues that will be addressed. Canvassing will continue. Members should return calls and be willing to discuss subjects or concerns. To help in dealing with the new "normal," they should consider couples counseling and support groups.
Dealing with cancer causes one to deal with mortality. Many well-adjusted men experience unfamiliar and severe emotional distress. By facing one's mortality the cancer diagnosis produces a grief reaction, with an initial response to acceptance of loss -loss of youth, of confidence in one's health, of recognition of his finite life.
The psychological benefit of accepting mortality is in the preservation of one's self concept, engaging in life with new conviction, and living more effectively in the present. In addition, the interim results show that tumors shrank in 61 of the 91 patients with cancer that had spread to soft tissue, including the liver and lungs. The drug was also shown to reduce bone pain as well as the need for narcotic painkillers, and to increase hemoglobin in patients with anemia, according to the company.
"These are provocative findings. Dual activity in bone and soft tissue hasn't been seen before," said Exelixis Chief Executive Officer Michael Morrissey.
After 12 weeks of treatment, some patients were randomized to either placebo or cabozantinib, but the trial was eventually unblinded when it became clear that the drug was effective. At a follow-up of 3.8 months, patients on placebo lived for a median of 40 days without their disease worsening.
Patients in the Phase 2 trial suffered from castration-resistant prostate cancer, meaning their tumor had stopped responding to hormone deprivation therapy.
Side effects seen in the trial included fatigue, high blood pressure, back pain and hand foot syndrome, a side effect of chemotherapy causing redness and peeling in the palms and soles of the feet.
Morrissey said Exelixis plans to launch three pivotal prostate cancer trials between the second half of this year and 2012. The first will focus on a composite of bone lesions and bone pain. Another will focus on preventing prostate cancer from spreading to bone and the third would focus on survival. What Shiozawa and his colleagues have been able to demonstrate, using a mouse model of metastasis, is that human prostate cancer cells are able to compete directly with HSCs for space in the mouse's bone marrow niche. They have also been able to show that increasing the size of the bone marrow niche leads to promotion of metastasis; by comparison, decreasing the size of the niche size reduces the probability of cell dissemination and therefore metastasis.
There are a variety of potential consequences of this new knowledge:
u If the bone marrow niche really does play a central role in metastasis of prostate cancer to bone, then researchers have another new target for drugs that may be able to prevent initiation and progression of bone metastasis.
Why prostate cancer cells can metastasize but become dormant R esearchers at the University of California, San Diego School of Medicine and Creighton University School of Medicine in Omaha have reported that markedly higher intake of vitamin D is needed to reach blood levels that can prevent or markedly cut the incidence of breast cancer and several other major diseases than had been originally thought.
"We found that daily intakes of vitamin D by adults in the range of 4000-8000 IU are needed to maintain blood levels of vitamin D metabolites in the range needed to reduce by about half the risk of several diseasesbreast cancer, colon cancer, multiple sclerosis, and type 1 diabetes," said Cedric Garland, Dr PH, professor of family and preventive medicine at UC San Diego Moores Cancer Center. "I was surprised to find that the intakes required to maintain vitamin D status for disease prevention were so high -much higher than the minimal intake of vitamin D of 400 IU/day that was needed to defeat rickets in the 20th century." "I was not surprised by this," said Robert P. Heaney, MD, of Creighton University, a distinguished biomedical scientist who has studied vitamin D need for several decades. "This result was what our dose-response studies predicted, but it took a study such as this, of people leading their everyday lives, to confirm it." "Most scientists who are actively working with vitamin D now believe that 40 to 60 ng/ml is the appropriate target concentration of 25-vitamin D in the blood for preventing the major vitamin D-deficiency related diseases, and have joined in a letter on this topic," said Garland. "Unfortunately, according a recent National Health and Nutrition Examination Survey, only 10 percent of the US population has levels in this range, mainly people who work outdoors."
Interest in larger doses was spurred in December of last year, when a National Academy of Sciences Institute of Medicine committee identified 4000 IU/day of vitamin D as safe for every day use by adults and children nine years and older, with intakes in the range of 1000-3000 IU/day for infants and children through age eight years old.
While the IOM committee states that 4000 IU/day is a safe dosage, the recommended minimum daily intake is only 600 IU/day. "Now that the results of this study are in, it will become common for almost every adult to take 4000 IU/day," Garland said. "This is comfortably under the 10,000 IU/day that the IOM Committee Report considers as the lower limit of risk, and the benefits are substantial." He added that people who may have contra-indications should discuss their vitamin D needs with their family doctor.
"Now is the time for virtually everyone to take more vitamin D to help prevent some major types of cancer, several other serious illnesses, and fractures," We believe PCC, as our national body, is in the perfect position to inquire how this Ontario policy is viewed by Support Groups here in Ontario (it would interesting as well to find out what other provinces are doing in this regard). Is the Ontario policy simply to save tax-payers' money at the expense of our members or is there a health rationale in pursuing active surveillance? PCCN Ottawa is requesting that PCC poll nationally to obtain feedback on this Ontario government policy. After this polling it would be appropriate to call a provincial meeting to discuss what our position should be. Once our position is determined, PCC could on our behalf articulate it to the Government of Ontario.
We believe this important issue needs to be addressed, now.
We look forward to your thoughts on a matter important to men and their families. In any event, the two had a valuable discussion and the other Warrior learned much from Ludwick's extensive knowledge of treatments and therapies for recurrent prostate cancers. and almost total loss of hearing. Shortly before his death he said, "Life is like a deck of cards and we need to play the hands we are dealt and make the best of it."
Happiest when around family and friends, it was also important to him to help those who had fallen victim to cancer, heart and stroke, and Parkinson's. A charitable man, he made a donation of $50,000 each to the Parkinson Society of Ottawa, the Canadian Cancer Society, the Heart and Stroke Foundation of Ontario, and the Prostate Cancer Association Ottawa, (now Prostate Cancer Canada Network Ottawa). Mr. Rickward's request in each case was that the sum paid "be used specifically for research." PCCN Ottawa thanked the family for the generous donation. Lori said her uncle did not have prostate cancer but recognized the disease's seriousness and wished to help in its research.
Aided by The Ottawa Hospital Foundation and the Ottawa Regional Cancer Foundation, PCCN Ottawa plans to identify suitable research projects in the area and make the donation on Mr. Rickward's behalf. He will be recognized for the donation and his nieces notified of how the money is being distributed.
